A Phase 3 interventional study of Pioglitazone Plus dapaglifliozin and Placebo in Risk Reduction, sponsored by Hamad Medical Corporation. Status unknown at 1 site in Qatar. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-07.
Sponsored by Hamad Medical Corporation · Phase 3, Interventional, and Health services research
The prevalence of type 2 diabetes mellitus (T2DM) in Qatar and nations worldwide has increased in recent decades into epidemic proportions. Cardiovascular (CVD) disease is the leading cause of death in T2DM patients. Approximately 80% of T2DM patients will die because of CV cause. Congestive heart failure (CHF) is a major cause of CV death in T2DM, and it also is responsible for significant morbidity and health care expenditure due to high rate of hospitalization for heart failure.
Community based studies have demonstrated similar prevalence of HF with reduced ejection fraction (HFpEF) and HF with reduced LV function (HFrEF) in patients hospitalized for CHF. Moreover, the prevalence of HFrEF is declining over the past two decades, whereas that of HFpEF is progressively increasing. Progressive increase in obesity and T2DM prevalence is likely among the principal factors responsible for the steady increase in HFpEF prevalence.
The aims of the present study are to examine whether therapies that correct the myocardial metabolic abnormalities present in subjects with T2DM and diastolic dysfunction improve myocardial diastolic dysfunction and reduce the rate of hospitalizations in patients with HFpEF
The primary objective of the study is to examine the effect of combination therapy with pioglitazone (15 mg) plus dapagliflozin (10 mg) versus placebo on hospitalization for heart failure in patients with HFpEF.
Eligible subjects, who consent for participating in the study, will be seen by the study coordinator. Medical history and physical examination will be performed. Each subject will receive the following measurements:
Medical history and physical examination including weight, height, waist, blood pressure and pulse.
Blood tests:
Screening: CBC, Blood chemistry, fasting plasma glucose concentration, HbA1c, renal and liver function, lipid profile, TSH, serum iron, iron biding capacity and ferritin.
Plasma metabolites: ketone, lactate, bicarbonate, venous PH and plasma free fatty acid.
Hormones: insulin, C-peptide, glucagon, NT proBNP, angiotensin II, plasma renin activity, and aldosterone.
Inflammatory markers: adiponectin, hsCRP, IL-2, IL-6 and IL-12, F2-isoprostane, oxidized LDL.
Vascular Measurements: Measurement of pulse wave velocity, and central aortic pulse pressure, with sphygmocor.
Measurement of total body fat mass with Bioimpedence. Echocardiography
Patients will be consented on the day of discharge or during the outpatient visit in the Cardiology Clinic. Consented patients will be referred to the CRC within one week to perform the echocardiography and vascular measurements. Patients will be asked to come to CRC after overnight fast and blood samples will be drawn for the above mentioned blood tests, after which echocardiography and vascular measurements will be performed.
Randomization and Intervention:
After completing the baseline studies, patients will be randomized into two groups to receive in a double blind fashion:
Group 1: combination of pioglitazone plus dapagliflozin, or Group 2: Placebo (Beta blockers, ACEI, ARB, and aldosterone )
Patients in both groups will be matched for age, gender, BMI, HbA1c, systolic BP and LVEF. Randomization will be made by the pharmacist at the Heart Hospital and the randomization code will be maintained at the hospital pharmacy. Patients will be randomized in blocks of 4 while the group means are matched for the above parameters
Hamad Medical Corporation is the lead sponsor of 133 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
We have limited the inclusion criteria in the present study to T2DM patients with HFpEF and evidence of diastolic dysfunction by echocardiography in order to select a homogenous group of HFpEF patients with similar etiology, likely "metabolic HFpEF". We believe that this subgroup of HFpEF will benefit most from treatment with low dose pioglitazone (15 mg) plus dapagliflozin (10 mg).
Exclusion Criteria:
Pioglitazone 15mg and dapaglifliozin 10mg together in T2DM patients having HF and HFpEF conditions
Drug: Pioglitazone Plus dapaglifliozin
Beta blockers, ACEI, ARB, and aldosterone
Drug: Placebo
Pioglitazone Plus dapaglifliozin
(Beta blockers, ACEI, ARB, and aldosterone )
Time to first hospitalization for heart failure after starting intervention
Hospitalization for heart failure will be defined as a hospitalization \>24 hours requiring intravenous diuretic infusion.
Time frame: 3 years
Number of all cause mortality
Composite outcome comprised of total mortality, incidence of acute coronary syndrome and non fatal CVA
Time frame: 3 years
Plan to share: No
This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hamad Medical Corporation